



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**June 23<sup>rd</sup>, 2015 6:00 – 8:30 p.m.**

- |  |                    |
|--|--------------------|
| <b>1. Executive Session</b>  | <b>6:00 - 6:30</b> |
| <b>2. Introductions and Approval of DUR Board Minutes</b><br>(Public Comment Prior to Board Action)  | <b>6:30 - 6:35</b> |
| <b>3. DVHA Pharmacy Administration Updates</b> <ul style="list-style-type: none"><li>▪ Updates</li></ul>   | <b>6:35 - 6:40</b> |
| <b>4. Medical Director Update</b> <ul style="list-style-type: none"><li>▪ Clinical Programs Update</li><li>▪ Prescriber Comments</li></ul>   | <b>6:40 – 6:45</b> |
| <b>5. Follow-up Items from Previous Meetings</b> <ul style="list-style-type: none"><li>▪ Data analysis of Amiodarone</li><li>▪ 2015 Retro DUR Initiatives schedule</li></ul>   | <b>6:45 - 7:00</b> |
| <b>6. RetroDUR/DUR</b>   | <b>7:00 – 7:00</b> |
| <b>7. Clinical Update: Drug Reviews</b><br>(Public comment prior to Board action)  | <b>7:00 – 7:30</b> |
| <b>Abbreviated New Drug Reviews</b> <ul style="list-style-type: none"><li>▪ Breo Ellipta® (fluticasone furoate/vilanterol)</li><li>▪ Saphris® (asenapine)</li></ul>  |                    |
| <b>Full New Drug Reviews</b> <ul style="list-style-type: none"><li>▪ Belsomra® (suvorexant)</li><li>▪ Evzio® (Naloxone HCL)</li><li>▪ Kitabis® (tobramycin solution)</li><li>▪ Onexton® (clindamycin phosphate &amp; benzoyl peroxide gel)</li><li>▪ Soolantra® (ivermectin)</li><li>▪ Spiriva® Respimat (tiotropium bromide)</li></ul>  |                    |
| <b>8. Therapeutic Drug Classes – Periodic Review</b><br>(Public comment prior to Board action) <ul style="list-style-type: none"><li>▪ Antihistamines, Second Generations</li><li>▪ Intranasal Agents</li><li>▪ Genital Warts and Actinic Keratosis Agents</li><li>▪ Idiopathic Pulmonary Fibrosis Agents</li><li>▪ Inflammatory Bowel Agents (Oral &amp; Rectal Products)</li><li>▪ Otic Anti-Infectives</li><li>▪ Pseudobulbar Affect Agents</li></ul> | <b>7:30 – 8:00</b> |

- |  |                    |
|--|--------------------|
| <b>9. New Managed Therapeutic Drug Classes</b><br>(Public comment prior to Board action) <ul style="list-style-type: none"><li>▪ Selected Contraceptive Products</li></ul>   | <b>8:00 – 8:15</b> |
| <b>10. Review of Newly-Developed/Revised<br/>Clinical Coverage Criteria and/or Preferred Products</b><br>(Public comment prior to Board action)  | <b>8:15 – 8:15</b> |
| <b>11. General Announcements</b><br><b>Selected FDA Safety Alerts</b><br>FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes<br>may result in a serious condition of too much acid in the blood<br><a href="http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm">http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm</a> | <b>8:15– 8:30</b>  |
| <b>12. Adjourn</b>   | <b>8:30</b>        |